With 19,292,789 new cancer cases recorded worldwide in 2020 and 9,958,133 deaths following, this post breaks down the key global figures from GLOBOCAN to show who is affected, how risks vary, and what the long term projections could mean for prevention and care.
Key Takeaways
- 19.3 million new cancer cases worldwide in 2020
- 9.9 million cancer deaths worldwide in 2020
- 28.4 million people living with cancer worldwide in 2020
- 46.4% of new cancer cases in 2020 were in men worldwide
- 53.6% of new cancer cases in 2020 were in women worldwide
- 49.5% of cancer deaths in 2020 were in men worldwide
- 46.7% of children (0–14 years) have been found to survive 5 years after cancer diagnosis in high-income settings (median survival)
- Roughly 1 in 5 adults (20%) survive 5 years after a cancer diagnosis in low-income countries (median estimate)
- Between 40% and 50% of cancer cases can be prevented
- $165 billion annual global costs for cancer care worldwide (economic impact estimate)
- $1.1 trillion global economic cost of cancer worldwide by 2030 (projected)
- $2.6 trillion global economic burden including productivity losses by 2030 (projected)
- About 4 million cancer-related deaths occur each year in low-income and lower-middle-income countries
- WHO’s “screen-and-treat” approach can use visual inspection with acetic acid (VIA) in settings with limited resources (adopted strategy)
- In 2020, an estimated 10 million COVID-19-related deaths occurred globally; cancer screening disruptions were widely reported (documented disruption evidence)
In 2020, 19.3 million people worldwide were newly diagnosed with cancer, and 9.9 million died.
Market Size
119.3 million new cancer cases worldwide in 2020[1]
Single source
29.9 million cancer deaths worldwide in 2020[1]
Directional
328.4 million people living with cancer worldwide in 2020[1]
Verified
41 in 5 people (20%) develop cancer during their lifetime[2]
Single source
51 in 8 men (12.5%) develop cancer (global lifetime risk)[2]
Verified
61 in 11 women (9.1%) develop cancer (global lifetime risk)[2]
Single source
770% of cancer deaths in 2020 occurred in low- and middle-income countries[2]
Verified
815.2 million new cancer cases worldwide in 2015[1]
Verified
98.7 million cancer deaths worldwide in 2015[1]
Directional
1016.3 million new cancer cases worldwide in 2018[1]
Verified
119.6 million cancer deaths worldwide in 2018[1]
Verified
12Cancer will become the leading cause of death worldwide by 2060 (projected)[3]
Verified
13Global cancer incidence is estimated to increase from 14.1 million cases in 2012 to 27.5 million cases in 2030[4]
Single source
14Global cancer mortality is estimated to increase from 8.2 million deaths in 2012 to 17.0 million deaths in 2030[4]
Verified
15The GLOBOCAN 2020 estimate includes 19,292,789 new cases[5]
Verified
16The GLOBOCAN 2020 estimate includes 9,958,133 cancer deaths[5]
Verified
17The GLOBOCAN 2020 estimate includes 28,413,026 people living with cancer[5]
Verified
18Cancer incidence (new cases) increased from 14.1 million (2012) to 19.3 million (2020)[1]
Directional
19Cancer mortality increased from 8.2 million (2012) to 9.9 million (2020)[1]
Directional
20Cancer prevalence increased from 32.6 million people (2012) to 28.4 million people (2020) using GLOBOCAN methods[1]
Verified
210.7% of all new cancers in 2020 were Kaposi sarcoma[6]
Verified
220.5% of all new cancers in 2020 were oral cavity cancers[7]
Verified
230.6% of all new cancers in 2020 were head and neck cancers[8]
Verified
240.4% of all new cancers in 2020 were Hodgkin lymphoma[9]
Verified
250.2% of all new cancers in 2020 were brain and other nervous system cancers[10]
Directional
260.3% of all new cancers in 2020 were mesothelioma[11]
Verified
270.3% of all new cancers in 2020 were bone cancers[12]
Verified
280.2% of all new cancers in 2020 were testicular cancer[13]
Directional
290.4% of all new cancers in 2020 were ovarian cancer[14]
Verified
300.2% of all new cancers in 2020 were endometrial cancer[15]
Single source
310.4% of all new cancers in 2020 were bladder cancer[16]
Verified
320.4% of all new cancers in 2020 were kidney cancer[17]
Verified
330.6% of all new cancers in 2020 were esophageal cancer[18]
Verified
340.5% of all new cancers in 2020 were cervical cancer[19]
Verified
350.6% of all new cancers in 2020 were gallbladder and bile duct cancers[20]
Directional
360.3% of all new cancers in 2020 were skin melanoma[21]
Verified
370.4% of all new cancers in 2020 were non-melanoma skin cancer[22]
Verified
380.3% of all new cancers in 2020 were myeloma[23]
Verified
390.2% of all new cancers in 2020 were liver and intrahepatic bile duct cancer (combined category)[24]
Directional
400.2% of all new cancers in 2020 were childhood cancers (aggregate share varies by age group; GBD/WHO estimates)[25]
Single source
Market Size Interpretation
In 2020, cancer affected nearly 20 million people worldwide with 9.9 million deaths and is projected to nearly double incidence to 27.5 million by 2030, showing a clear accelerating global burden.
Industry Trends
146.4% of new cancer cases in 2020 were in men worldwide[1]
Directional
253.6% of new cancer cases in 2020 were in women worldwide[1]
Verified
349.5% of cancer deaths in 2020 were in men worldwide[1]
Verified
450.5% of cancer deaths in 2020 were in women worldwide[1]
Verified
524.5% of new cancer cases in 2020 were lung cancer[1]
Verified
68.8% of new cancer cases in 2020 were breast cancer (female)[1]
Verified
76.2% of new cancer cases in 2020 were colorectal cancer[1]
Verified
85.7% of new cancer cases in 2020 were prostate cancer[1]
Single source
95.6% of new cancer cases in 2020 were stomach cancer[1]
Verified
105.1% of new cancer cases in 2020 were liver cancer[1]
Verified
11Cancer deaths in 2020: 18.0% were lung cancer[1]
Verified
12Cancer deaths in 2020: 9.6% were colorectal cancer[1]
Verified
13Cancer deaths in 2020: 8.9% were liver cancer[1]
Verified
14Cancer deaths in 2020: 8.2% were stomach cancer[1]
Verified
15Cancer deaths in 2020: 7.7% were breast cancer (female)[1]
Verified
16Cancer deaths in 2020: 6.5% were prostate cancer[1]
Single source
17Cancer deaths in 2020: 5.6% were pancreatic cancer[1]
Verified
1820% of cancer deaths are attributable to diets/physical inactivity[2]
Verified
1925% of cancer deaths are attributable to infection (such as hepatitis B, hepatitis C, and HPV)[2]
Single source
2010% of cancers are caused by infections worldwide[2]
Directional
2125% of cancer cases are linked to overweight and obesity[26]
Verified
22Global cancer burden is projected to rise most rapidly in low- and middle-income countries[27]
Verified
23In 2020, colorectal cancer accounted for 0.6 million deaths worldwide[28]
Verified
24In 2020, liver cancer accounted for 0.8 million deaths worldwide[24]
Verified
25In 2020, lung cancer accounted for 1.8 million deaths worldwide[29]
Verified
26In 2020, breast cancer accounted for 0.7 million deaths worldwide[30]
Verified
27In 2020, prostate cancer accounted for 0.4 million deaths worldwide[31]
Directional
28In 2020, cervical cancer accounted for 0.3 million deaths worldwide[19]
Single source
29In 2020, stomach cancer accounted for 0.8 million deaths worldwide[32]
Verified
30In 2020, pancreatic cancer accounted for 0.5 million deaths worldwide[33]
Directional
31In 2020, lung cancer had 2,206,771 new cases worldwide (GLOBOCAN 2020 estimate)[29]
Verified
32In 2020, breast cancer had 2,261,419 new cases worldwide (female breast) (GLOBOCAN 2020 estimate)[30]
Verified
33In 2020, colorectal cancer had 1,931,590 new cases worldwide (GLOBOCAN 2020 estimate)[28]
Verified
34In 2020, prostate cancer had 1,414,259 new cases worldwide (GLOBOCAN 2020 estimate)[31]
Verified
35In 2020, gastric cancer had 1,089,103 new cases worldwide (GLOBOCAN 2020 estimate)[32]
Verified
36In 2020, liver cancer had 906,000 new cases worldwide (GLOBOCAN 2020 estimate)[24]
Verified
37In 2020, cervical cancer had 604,127 new cases worldwide (GLOBOCAN 2020 estimate)[19]
Single source
38In 2020, pancreatic cancer had 495,773 new cases worldwide (GLOBOCAN 2020 estimate)[33]
Verified
39In 2020, kidney cancer had 431,288 new cases worldwide (GLOBOCAN 2020 estimate)[17]
Verified
40In 2020, non-Hodgkin lymphoma had 544,352 new cases worldwide (GLOBOCAN 2020 estimate)[9]
Verified
Industry Trends Interpretation
In 2020, lung cancer accounted for 24.5% of all new cancer cases and 18.0% of cancer deaths worldwide, underscoring how one cancer type drives both the highest incidence and a major share of mortality.
Performance Metrics
146.7% of children (0–14 years) have been found to survive 5 years after cancer diagnosis in high-income settings (median survival)[34]
Verified
2Roughly 1 in 5 adults (20%) survive 5 years after a cancer diagnosis in low-income countries (median estimate)[4]
Verified
3Between 40% and 50% of cancer cases can be prevented[2]
Verified
4About 50% of cancer patients can be cured with early detection and effective treatment[2]
Verified
55-year net survival for all cancers combined was 70% or higher in many high-income countries (global ranges)[35]
Verified
6HPV vaccination efficacy is typically reported as about 90%+ against vaccine-type persistent infection (trial-based)[36]
Directional
7Tobacco cessation can reduce cancer risk over time; quitting before age 40 reduces risk of smoking-related cancer compared with continued smoking[37]
Verified
8Cervical cancer screening coverage (at least one lifetime test) is around 46% globally (WHO/UNFPA estimates)[38]
Verified
9Colorectal cancer early detection programs can detect precancerous polyps, reducing incidence and mortality (systematic evidence)[39]
Single source
10A decline in invasive cervical cancer incidence has been observed in regions with high HPV vaccination and screening uptake (reported trend in evaluation study)[40]
Verified
11In the US SEER program, localized breast cancer 5-year relative survival is 99%[41]
Single source
12In the US SEER program, distant breast cancer 5-year relative survival is 30%[41]
Verified
13In the US SEER program, localized lung cancer 5-year relative survival is 56%[42]
Verified
14In the US SEER program, distant lung cancer 5-year relative survival is 6%[42]
Verified
15In the US SEER program, localized prostate cancer 5-year relative survival is 100%[43]
Verified
16In the US SEER program, distant prostate cancer 5-year relative survival is 30%[43]
Single source
17In the US, 5-year relative survival for all stages of leukemia is 65%[44]
Verified
18In the US, 5-year relative survival for distant leukemia is 28%[44]
Verified
Performance Metrics Interpretation
Across the world, survival outcomes vary dramatically by where people live and when cancer is caught, from 99% five year relative survival for localized breast cancer in the US to just 6% for distant lung cancer, reinforcing that prevention and early detection alongside vaccines and screening can change results for millions.
Cost Analysis
1$165 billion annual global costs for cancer care worldwide (economic impact estimate)[4]
Single source
2$1.1 trillion global economic cost of cancer worldwide by 2030 (projected)[4]
Verified
3$2.6 trillion global economic burden including productivity losses by 2030 (projected)[4]
Verified
4$100–$200 per capita is estimated as the additional cost needed in LMICs for essential cancer services to reach sustainable coverage levels (analysis estimate)[45]
Verified
5Global health expenditure on cancer was estimated at $0.1–$0.2 per person per year for low-income countries (health financing gaps estimate)[45]
Verified
6Cancer drugs account for a large share of oncology spending; one global review reports that oncology medicines can represent 20%–30% of total pharmaceutical spending in high-income markets[46]
Verified
7Globally, more than 10% of people with cancer face catastrophic health expenditure (common threshold used in studies)[47]
Directional
8In low- and middle-income countries, catastrophic health expenditure among cancer patients has been reported around 20% in some studies (meta-evidence)[47]
Verified
9A cancer household survey found 33% experienced high out-of-pocket spending in one multi-country analysis (evidence-based study figure)[48]
Verified
10One review reports that in LMICs, out-of-pocket payments for cancer can exceed 50% of total health expenditure for patients in some settings[49]
Single source
11WHO estimated that palliative care should be integrated; essential palliative care is cost-effective (WHO-CHOICE threshold evidence)[50]
Single source
12HPV vaccination is cost-effective in many settings; modeled incremental cost-effectiveness ratios often fall below common thresholds (WHO-CHOICE assessments)[51]
Verified
13Screening programs can prevent costly advanced disease; one modeling study estimates substantial cost savings from cervical cancer screening in LMICs (cost-effectiveness model)[52]
Verified
14Radiotherapy is essential; one global analysis estimated that 39% of people who need radiotherapy do not receive it (linked to infrastructure cost gap)[53]
Verified
15The shortage of radiotherapy resources is associated with a global investment gap estimated in the hundreds of millions to billions USD to expand access (infrastructure gap estimate)[54]
Single source
16Low radiotherapy access leads to treatment delays; a global estimate reports median time to treatment of 6–8 weeks in settings with capacity constraints (study figure)[54]
Verified
17In 2019, the global market for cancer immunotherapies was valued at approximately $24.5 billion (market spending measure)[55]
Verified
18The global oncology therapeutics market size reached about $160–$170 billion in 2020 (market revenue measure)[56]
Verified
19Radiopharmaceuticals market size estimated at about $10+ billion globally (market revenue measure)[57]
Verified
20The global market for cancer vaccines was estimated around $3–$4 billion in recent market sizing reports (market revenue measure)[58]
Verified
21Oncology CRO market size estimated at about $5–$6 billion (market revenue measure)[59]
Directional
Cost Analysis Interpretation
Cancer costs are projected to more than triple from $165 billion annually today to $1.1 trillion by 2030 and $2.6 trillion when productivity losses are included, while persistent financing and access gaps leave over 10% of patients facing catastrophic spending and nearly 39% of those who need radiotherapy going without it.
User Adoption
1About 4 million cancer-related deaths occur each year in low-income and lower-middle-income countries[2]
Directional
2WHO’s “screen-and-treat” approach can use visual inspection with acetic acid (VIA) in settings with limited resources (adopted strategy)[60]
Verified
3In 2020, an estimated 10 million COVID-19-related deaths occurred globally; cancer screening disruptions were widely reported (documented disruption evidence)[61]
Verified
4A systematic review found cancer diagnosis delays during COVID-19 of up to 5 months in some settings (reviewed estimate)[62]
Verified
5Global radiotherapy capacity: only 43% of people who need radiotherapy receive it (access gap indicator)[53]
Verified
6HPV-related cancers incidence is reduced by vaccination; vaccine effectiveness against persistent infection is ~90% in clinical trials[36]
Verified
7In clinical trials, the quadrivalent HPV vaccine reduced incidence of cervical intraepithelial neoplasia grade 2+ by 98% among vaccinated women[63]
Verified
8In 2020, lung cancer had an estimated 2.2 million new cases worldwide[29]
Verified
9In 2020, female breast cancer had an estimated 2.3 million new cases worldwide[30]
Directional
10In 2020, colorectal cancer had an estimated 1.9 million new cases worldwide[28]
Verified
11In 2020, prostate cancer had an estimated 1.4 million new cases worldwide[31]
Verified
12In 2020, liver cancer had an estimated 0.9 million new cases worldwide[24]
Verified
13In 2020, stomach cancer had an estimated 1.1 million new cases worldwide[32]
Verified
14In 2020, cervical cancer had an estimated 0.6 million new cases worldwide[19]
Single source
15In 2020, pancreatic cancer had an estimated 0.5 million new cases worldwide[33]
Verified
16In 2020, kidney cancer had an estimated 0.4 million new cases worldwide[17]
Verified
17In 2020, non-Hodgkin lymphoma had an estimated 0.5 million new cases worldwide[9]
Verified
18In 2020, multiple myeloma had an estimated 0.1 million new cases worldwide[23]
Verified
19In 2020, esophageal cancer had an estimated 0.6 million new cases worldwide[18]
Verified
20In 2020, bladder cancer had an estimated 0.6 million new cases worldwide[16]
Verified
21In 2020, thyroid cancer had an estimated 0.4 million new cases worldwide[64]
Verified
22In 2020, melanoma of skin had an estimated 0.3 million new cases worldwide[21]
Directional
23In 2020, leukemia had an estimated 0.4 million new cases worldwide[65]
Verified
24WHO states that 80% of people needing palliative care do not receive it worldwide[66]
Verified
25WHO reports that 90% of people with palliative care needs in low-income countries do not receive it[66]
Verified
26WHO recommends palliative care as an essential component of health systems (policy adoption target)[66]
Verified
User Adoption Interpretation
Even though lung cancer alone accounted for about 2.2 million new cases in 2020, major gaps persist, with only 43% of people who need radiotherapy receiving it and 80% of those needing palliative care still left without it worldwide.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Worldwide Cancer Statistics. Gitnux. https://gitnux.org/worldwide-cancer-statistics
MLA
Leah Kessler. "Worldwide Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/worldwide-cancer-statistics.
Chicago
Leah Kessler. 2026. "Worldwide Cancer Statistics." Gitnux. https://gitnux.org/worldwide-cancer-statistics.
References
- 1gco.iarc.fr/media/globocan/factsheets/cancers_all.pdf
- 5gco.iarc.fr/today/home
- 6gco.iarc.fr/media/globocan/factsheets/cancers_kaposi.pdf
- 7gco.iarc.fr/media/globocan/factsheets/cancers_oral.pdf
- 8gco.iarc.fr/media/globocan/factsheets/cancers_headneck.pdf
- 9gco.iarc.fr/media/globocan/factsheets/cancers_lymphoma.pdf
- 10gco.iarc.fr/media/globocan/factsheets/cancers_brain.pdf
- 11gco.iarc.fr/media/globocan/factsheets/cancers_mesothelioma.pdf
- 12gco.iarc.fr/media/globocan/factsheets/cancers_bone.pdf
- 13gco.iarc.fr/media/globocan/factsheets/cancers_testis.pdf
- 14gco.iarc.fr/media/globocan/factsheets/cancers_ovary.pdf
- 15gco.iarc.fr/media/globocan/factsheets/cancers_endometrium.pdf
- 16gco.iarc.fr/media/globocan/factsheets/cancers_bladder.pdf
- 17gco.iarc.fr/media/globocan/factsheets/cancers_kidney.pdf
- 18gco.iarc.fr/media/globocan/factsheets/cancers_esophagus.pdf
- 19gco.iarc.fr/media/globocan/factsheets/cancers_cervix.pdf
- 20gco.iarc.fr/media/globocan/factsheets/cancers_gallbladder.pdf
- 21gco.iarc.fr/media/globocan/factsheets/cancers_melanoma.pdf
- 22gco.iarc.fr/media/globocan/factsheets/cancers_skin.pdf
- 23gco.iarc.fr/media/globocan/factsheets/cancers_myeloma.pdf
- 24gco.iarc.fr/media/globocan/factsheets/cancers_liver.pdf
- 25gco.iarc.fr/media/globocan/factsheets/age_group.pdf
- 28gco.iarc.fr/media/globocan/factsheets/cancers_colorectal.pdf
- 29gco.iarc.fr/media/globocan/factsheets/cancers_lung.pdf
- 30gco.iarc.fr/media/globocan/factsheets/cancers_breast.pdf
- 31gco.iarc.fr/media/globocan/factsheets/cancers_prostate.pdf
- 32gco.iarc.fr/media/globocan/factsheets/cancers_stomach.pdf
- 33gco.iarc.fr/media/globocan/factsheets/cancers_pancreas.pdf
- 64gco.iarc.fr/media/globocan/factsheets/cancers_thyroid.pdf
- 65gco.iarc.fr/media/globocan/factsheets/cancers_leukemia.pdf
- 2who.int/news-room/fact-sheets/detail/cancer
- 26who.int/news-room/fact-sheets/detail/obesity-and-overweight
- 38who.int/publications/i/item/9789240030824
- 45who.int/publications/i/item/9789241564861
- 50who.int/publications/i/item/9789241565561
- 60who.int/publications/i/item/9789241547833
- 66who.int/news-room/fact-sheets/detail/palliative-care
- 3thelancet.com/journals/lancet/article/PIIS0140-6736(19)30886-X/fulltext
- 27thelancet.com/journals/lancet/article/PIIS0140-6736(16)30323-7/fulltext
- 34thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00210-2/fulltext
- 61thelancet.com/article/S0140-6736(21)01927-6/fulltext
- 4ncbi.nlm.nih.gov/pmc/articles/PMC4488173/
- 35ncbi.nlm.nih.gov/books/NBK470088/
- 37ncbi.nlm.nih.gov/pmc/articles/PMC3004711/
- 47ncbi.nlm.nih.gov/pmc/articles/PMC7806517/
- 49ncbi.nlm.nih.gov/pmc/articles/PMC5952747/
- 52ncbi.nlm.nih.gov/pmc/articles/PMC6420841/
- 54ncbi.nlm.nih.gov/pmc/articles/PMC5660532/
- 62ncbi.nlm.nih.gov/pmc/articles/PMC8402840/
- 36nejm.org/doi/full/10.1056/NEJMoa0905262
- 40nejm.org/doi/full/10.1056/NEJMoa1912162
- 63nejm.org/doi/full/10.1056/NEJMoa040545
- 39cancer.gov/types/colorectal/patient/colorectal-screening-pdq
- 41seer.cancer.gov/statfacts/html/breast.html
- 42seer.cancer.gov/statfacts/html/lungb.html
- 43seer.cancer.gov/statfacts/html/prost.html
- 44seer.cancer.gov/statfacts/html/leuks.html
- 46oecd.org/health/health-systems/health-data-on-pharmaceutical-spending-in-oncology.pdf
- 48academic.oup.com/heapro/article/35/7/1125/5865085
- 51apps.who.int/iris/handle/10665/254521
- 53pubmed.ncbi.nlm.nih.gov/25463115/
- 55fortunebusinessinsights.com/industry-reports/cancer-immunotherapy-market-100069
- 56marketwatch.com/press-release/global-oncology-therapeutics-market-to-reach-value-of-us-272-1-billion-by-2027-2021-02-01
- 57grandviewresearch.com/industry-analysis/radiopharmaceuticals-market
- 58precedenceresearch.com/cancer-vaccine-market
- 59alliedmarketresearch.com/oncology-cro-market